和黄医药（中国）周二表示，英瑞制药商阿斯利康已向美国食品药品监督管理局提交了ORPATHYS-TAGRISSO组合疗法用于治疗晚期肺癌患者的上市申请。
HUTCHMED (China) said on Tuesday that Anglo-Swedish drugmaker AstraZeneca had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination to treat patients with advanced lung cancer.